» Articles » PMID: 10545916

Induction of Endogenous Bcl-xS Through the Control of Bcl-x Pre-mRNA Splicing by Antisense Oligonucleotides

Overview
Journal Nat Biotechnol
Specialty Biotechnology
Date 1999 Nov 5
PMID 10545916
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to apoptosis, which plays an important role in tumors that are refractory to chemotherapy, is regulated by the ratio of antiapoptotic to proapoptotic proteins. By manipulating levels of these proteins, cells can become sensitized to undergo apoptosis in response to chemotherapeutic agents. Alternative splicing of the bcl-x gene gives rise to two proteins with antagonistic functions: Bcl-xL, a well-characterized antiapoptotic protein, and Bcl-xS, a proapoptotic protein. We show here that altering the ratio of Bcl-xL to Bcl-xS in the cell using an antisense oligonucleotide permitted cells to be sensitized to undergo apoptosis in response to ultraviolet B radiation and chemotherapeutic drug treatment. These results demonstrate the ability of a chemically modified oligonucleotide to alter splice site selection in an endogenous gene and illustrate a powerful tool to regulate cell survival.

Citing Articles

Antisense oligonucleotide-mediated TRA2β poison exon inclusion induces the expression of a lncRNA with anti-tumor effects.

Leclair N, Brugiolo M, Park S, Devoucoux M, Urbanski L, Angarola B Nat Commun. 2025; 16(1):1670.

PMID: 39955311 PMC: 11829967. DOI: 10.1038/s41467-025-56913-8.


Targeting the conserved active site of splicing machines with specific and selective small molecule modulators.

Silvestri I, Manigrasso J, Andreani A, Brindani N, Mas C, Reiser J Nat Commun. 2024; 15(1):4980.

PMID: 38898052 PMC: 11187226. DOI: 10.1038/s41467-024-48697-0.


RNA splicing dysregulation and the hallmarks of cancer.

Bradley R, Anczukow O Nat Rev Cancer. 2023; 23(3):135-155.

PMID: 36627445 PMC: 10132032. DOI: 10.1038/s41568-022-00541-7.


Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition.

Madanayake T, Welsh E, Darville L, Koomen J, Chalfant C, Haura E Nucleic Acid Ther. 2022; 32(5):391-400.

PMID: 35861718 PMC: 9595651. DOI: 10.1089/nat.2021.0101.


Development of a Prognostic Alternative Splicing Signature Associated With Tumor Microenvironment Immune Profiles in Lung Adenocarcinoma.

Bao G, Li T, Guan X, Yao Y, Liang J, Xiang Y Front Oncol. 2022; 12:880478.

PMID: 35832557 PMC: 9271776. DOI: 10.3389/fonc.2022.880478.